Clinical Report: Extracellular Vesicles in Immune Responses in Breast Cancer

Overview

This review highlights the role of extracellular vesicles (EVs) in modulating immune responses in breast cancer, particularly through immune checkpoint regulation. It emphasizes the impact of EVs on T-cell function.

Background

Breast cancer is a leading cause of cancer-related deaths, with immune evasion playing a critical role in its progression and treatment resistance. The tumor microenvironment (TME) is complex and influences immune responses.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• Extracellular vesicles (EVs) are key mediators of communication between tumor and immune cells.
• EVs contribute to immunosuppression by impairing T-cell function and promoting immune tolerance.
• PD-L1 and CTLA-4 are significant EV-associated proteins that drive immune evasion in breast cancer.
• Breast cancer subtypes exhibit different responses to EV-mediated immune modulation.

Clinical Implications

Clinicians should consider the heterogeneity of breast cancer subtypes when evaluating treatment responses.

Conclusion

The review discusses the role of EVs in immune checkpoint regulation in breast cancer.

Related Resources & Content

1. BMC Medicine, 2026 -- Frozen melanoma tissues yield extracellular vesicles with preserved diagnostic and immunogenic properties
2. Dana-Farber, 2026 -- Immune Activity Shift a Key Early Step in Breast Cancer Formation
3. Frontiers in Immunology, 2026 -- Organ-specific pre-metastatic and metastatic niches in colorectal cancer: “discrepancy in response to immune checkpoint inhibitors in liver and lung metastasis”
4. DailyMed -- KEYTRUDA- pembrolizumab injection, powder, lyophilized, for solution
5. New England Journal of Medicine, 2024 -- Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
6. Frontiers, 2026 -- An updated review on the role of extracellular vesicles in immune system modulation in breast cancer with special emphasis on immune checkpoint regulators
7. Frontiers in Immunology — Editorial: Cancer Immunosurveillance
8. DailyMed - KEYTRUDA- pembrolizumab injection, powder, lyophilized, for solution KEYTRUDA- pembrolizumab injection, solution
9. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer | New England Journal of Medicine
10. Frontiers | An updated review on the role of extracellular vesicles in immune system modulation in breast cancer with special emphasis on immune checkpoint regulators